Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression

Experimental Hematology

Volumn 39, Issue 8, 2011, Pages

  Sasaki, Nana ^a,b   Kuroda, Junya ^a,b   Nagoshi, Hisao ^a,b   Yamamoto, Mio ^a,b   Kobayashi, Satoru ^b   Tsutsumi, Yasuhiko ^a,b   Kobayashi, Tsutomu ^a,b   Shimura, Yuji ^a,b   Matsumoto, Yosuke ^a,b   Taki, Tomohiko ^b   Nishida, Kazuhiro ^a,b   Horiike, Shigeo ^a,b   Akao, Yukihiro ^c   Taniwaki, Masafumi ^a,b  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c GIFU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

10058 F 4; 5 (4 ETHYLBENZYLIDINE) 2 THIOXOTHIAZOLIDIN 4 ONE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MICRORNA; MICRORNA 143; MYC PROTEIN; NAVITOCLAX; PREDNISOLONE; PROTEIN BCL 2; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

AGED; ARTICLE; CANCER STAGING; CASE REPORT; CELL DEATH; CELL VIABILITY; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME INHIBITION; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPING; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MALE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79960631098     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.05.002     Document Type: Article

References (62)

1. Jack A., Barrans S. Recent advances in the understanding of aggressive B-cell lymphomas. Curr Diagn Pathol 2004, 10:360-373.
2. Carbone A., Gloghini A., Aiello A., Testi A., Cabras A. B-cell lymphomas with features intermediate between distinct pathologic entities. From pathogenesis to pathology. Hum Pathol 2010, 41:621-631.
3. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348:331-333.
4. Cory S., Vaux D.L., Strasser A., Harris A.W., Adams J.M. Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation. Cancer Res 1999, 59(suppl):1685s-1692s.
5. Smith S.M., Anastasi J., Cohen K.S., Godley L.A. The impact of MYC expression in lymphoma biology: beyond Burkitt lymphoma. Blood Cell Mol Dis 2010, 45:317-323.
6. Macpherson N., Lesack D., Klasa R., et al. Small noncleaved, non-Burkitt's (Burkitt-like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. J Clin Oncol 1999, 17:1558-1567.
7. Klapproth K., Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol 2010, 149:484-497.
8. Le Gouill S., Talmant P., Touzeau C., et al. The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 2007, 92:1335-1342.
9. Snuderl M., Kolman O.K., Chen Y.B., et al. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 2010, 34:327-340.
10. Kluin P.M., Harris N.L., Stein H., et al. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 265-266. IARC Press, Lyon. S.H. Swerdlow, E. Campo, N.L. Harris (Eds.).
11. Kuroda J., Kimura S., Akaogi T., et al. c-myc overexpression is not mandatory in aggressive-phase multiple myeloma with Burkitt's type translocation. Ann Hematol 2000, 79:514-518.
12. Kakazu N., Bar-Am I., Hada S., Ago H., Abe T. A new chromosome banding technique, spectral color banding (SCAN), for full characterization of chromosomal abnormalities. Gene Chromosome Cancer 2003, 37:412-416.
13. Taniwaki M., Sliverman G.A., Nishida K., et al. Translocations and amplification of the BCL2 gene are detected in interphase nuclei of non-Hodgkin's lymphoma by in situ hybridization with yeast artificial chromosome clones. Blood 1995, 86:1481-1486.
14. Akao Y., Nakagawa Y., Kitade Y., Kinoshita T., Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci 2007, 98:1914-1920.
15. Kuroda J., Puthalakath H., Cragg M.S., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006, 103:14907-14912.
16. Kuroda J., Kimura S., Strasser A., et al. Apoptosis-based dual molecular targeting by INNO-406, a second generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of anti-apoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007, 14:1667-1677.
17. Kuroda J., Kimura S., Andreeff M., et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myelogenous leukaemias with diverse drug resistance mechanisms. Br J Haematol 2008, 140:181-190.
18. Mason K.D., Khaw S.L., Rayeroux K.C., et al. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009, 23:2034-2041.
19. Oltersdorf T., Elmore S.W., Shoemaker A.R., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
20. Gomez-Curet I., Perkins R.S., Bennett R., Feidler K.L., Dunn S.P., Krueger L.J. c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg 2006, 41:207-211.
21. Huang M., Cheng Y., Liu C., Lin S., Liu H.E. A small-molecule c-Myc inhibitor, 10058-F4, induces cell cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia. Exp Hematol 2003, 34:1480-1489.
22. Kuroda J., Kimura S., Segawa H., et al. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 2003, 102:2229-2235.
23. Beck-Engeser G.B., Lum A.M., Huppi K., Caplen N.J., Wang B.B., Wabl M. Pvt1-encoded microRNAs in oncogenesis. Retrovirology 2008, 5:4.
24. Carramusa L., Contino F., Ferro A., et al. The PVT-1 oncogene is a Myc protein target that is overexpressed in transformed cells. J Cell Physiol 2007, 213:511-518.
25. Sachdeva M., Zhu S., Wu F., et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A 2009, 106:3207-3212.
26. van Delft M.F., Wei A.H., Mason K.D., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
27. Lam L.T., Lu X., Zhang H., Lesniewski R., Rosenberg S., Semizarov D. A microRNA screen to identify modulators of sensitivity to BCL2 inhibitor ABT-263 (navitoclax). Mol Cancer Ther 2010, 9:2943-2950.
28. Huang J.Z., Sanger W.G., Greiner T.C., et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002, 99:2285-2290.
29. Iqbal J., Sanger W.G., Horsman D.E., et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004, 165:159-166.
30. Akasaka T., Akasaka H., Ueda C., et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol 2000, 18:510-518.
31. Johnson N.A., Savage K.J., Ludkovski O., et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009, 114:2273-2279.
32. Savage K.J., Gascoyne R.D. Molecular signatures of lymphoma. Int J Hematol 2004, 80:401-419.
33. Bea S., Colomo L., Lopez-Guillermo A., et al. Clinicopathologic significance and prognostic vale of chromosomal imbalances in diffuse large B-cell lymphomas. J Clin Oncol 2004, 22:3498-3506.
34. Monni O., Joensuu H., Franssila K., Knuutila S. DNA copy number changes in diffuse large B-cell lymphoma-comparative genomic hybridization study. Blood 1996, 87:5269-5278.
35. Monni O., Joensuu H., Franssila K., Klefstrom J., Alitalo K., Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 1997, 90:1168-1174.
36. Stasik C.J., Nitta H., Zhang W., et al. Increased MYC gene copy number correlates with increased mRNA levels in diffuse large B-cell lymphoma. Haematologica 2010, 95:597-603.
37. Barrans S., Crouch S., Smith A., et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol 2010, 28:3360-3365.
38. Mounier N., Briere J., Gisselbrecht C., et al. Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma. Haematologica 2006, 91:715-716.
39. Pegoraro L., Palumbo A., Erikson J., et al. A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A 1984, 81:7166-7170.
40. Matsuzaki H., Hata H., Asou N., et al. Establishment and characterization of acute B-cell lymphocytic leukemia cell line showing (8;14) and (14;18) chromosome translocation. Acta Haematol 1990, 84:156-161.
41. Lambrechts A.C., Dorssers L.C., Hupkes P.E., et al. Genomic organization of the translocations (8;14) and (14;18) in a new lymphoma cell line. Leukemia 1994, 8:1164-1171.
42. Sambade C., Sällström J., Wiklund H.J., et al. A novel human B-cell line (U-2904) bearing t(8;14) and t(14;18) translocations. Int J Cancer 1995, 63:710-715.
43. Denyssevych T., Lestou V.S., Knesevich S., et al. Establishment and comprehensive analysis of a new human transformed follicular lymphoma B cell line, Tat-1. Leukemia 2002, 16:276-283.
44. Taira T., Nagasaki A., Tomoyose T., et al. Establishment of a human herpes virus-8-negative malignant effusion lymphoma cell line (STR-428) carrying concurrent translocations of BCL2 and c-MYC genes. Leuk Res 2007, 31:1285-1292.
45. Boström H., Leuchowius K.J., Hallböök H., et al. U-2973, a novel B-cell line established from a patient with a mature B-cell leukemia displaying concurrent t(14;18) and MYC translocation to a non-IG gene partner. Eur J Haematol 2008, 81:218-225.
46. Mohammad R.M., Mohamed A.N., Smith M.R., Jawadi N.S., al-Katib A. A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet 1993, 70:62-67.
47. Chang H., Messner H.A., Wang X.H., et al. A human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest 1992, 89:1014-1020.
48. Farrugia M.M., Duan L.J., Reis M.D., Ngan B.Y., Berinstein N.L. Alterations of the p53 tumor suppressor gene in diffuse large cell lymphomas with translocations of the c-MYC and BCL-2 proto-oncogenes. Blood 1994, 83:191-198.
49. Cragg M.S., Kuroda J., Puthalakath H., Huang D.C., Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007, 4:1681-1690.
50. Ackler S., Mitten M.J., Foster K., et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 2010, 66:869-880.
51. Kang M.H., Kang Y.H., Szymanska B., et al. Activity of vincristine, L-ASP, and dexthamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
52. Larsson L., Henriksson M.K. The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. Exp Cell Res 2010, 316:1429-1437.
53. Afanasyeva E.A., Komarova E.Y., Larsson L., Bahram F., Margulis B.A. Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. Int J Cancer 2007, 121:2615-2651.
54. Kimura S., Maekawa T., Hirakawa K., Murakami A., Abe T. Alterations of c-myc expression by antisense oligonucleotides enhance the induction of apoptosis in HL-60 cells. Cancer Res 1995, 55:1379-1384.
55. Cutrona G., Carpaneto E.M., Ponzanelli A., et al. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the Eμ enhancer. Cancer Res 2003, 63:6144-6148.
56. Karlsson A., Deb-Basy D., Cherry A., Turner S., Ford J., Felsher D.W. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci U S A 2003, 100:9974-9979.
57. Shackleton M., Quintana E., Fearon E.R., Morrison S.J. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138:822-829.
58. Wong D.J., Liu H., Ridky T.W., Cassarino D., Segal E., Chang H.Y. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2008, 2:333-344.
59. Ben-Porath I., Thompson M.W., Carey V.J., et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 2008, 40:499-507.
60. Zhuang D., Mannava S., Grachtchouk V., et al. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melenamoa cells. Oncogene 2008, 27:6623-6634.
61. Wu C.H., van Riggelen J., Yetil A., Fan A.C., Bachireddy P., Felsher D.W. Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation. Proc Natl Acad Sci U S A 2007, 104:13028-13033.
62. Wilson W.H., O'Connor O.A., Czuczman M.S., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.